Synopsis Clinical evidence suggests that Lorcaserin facilitate the sustained weight loss without a higher rate of major cardiovascular events in obese patients. The present study aims to assess the long-term cardiovascular and metabolic safety and efficacy of Lorcaserin in obese or overweight patients with the established atherosclerotic cardiovascular disease or multiple cardiovascular risk factors. This week’s “ MED FACT ” discusses a clinical study from The New England Journal of Medicine, “ Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients ”. Aug 26, 2018. Authors : E.A. Bohula; S.D.
Wiviott; D.K. McGuire; et. al. Key Takeaways: Lorcaserin lowers the cardiovascular risk among obese patients who were at high cardiovascular risk. Objective: To assess the long-term cardiovascular and metabolic safety and efficacy of Lorcaserin in obese patients. Study Type:…
